[[{“value”:”
According to a survey from Germany-based medical cannabis company Bloomwell GmBh, 94% of respondents that consumed cannabis did so for at least one medical or health reason. The most common reason cited by respondents for consuming cannabis was for stress relief (about 60%), followed by sleeping disorders (50.4%) and pain relief (35%).Â
However, just 10% of respondents said they had acquired cannabis exclusively from licensed pharmacies within the past year, while the vast majority â 79.6% â said they have had negative experiences with the unlicensed market.  Â
In a statement, Niklas Kouparanis, Co-Founder and CEO, Bloomwell Group GmbH, the holding company for Bloomwell Gmbh, said the survey response illustrates the âimmense potential and room for growth of the countryâs rapidly expanding medical cannabis industry following the implementation of the Cannabis Act on April 1, 2024, which rescheduled cannabis as a non-narcotic.â He added that according to the data, âmore than 20 million people in Germany could benefit from access to medical cannabis therapy.â  Â
The survey found that 30.9% reported purchasing cannabis that was of poor quality, 29%Â were afraid that illegally acquired cannabis will have a negative impact on their own health, 39.7 %Â are afraid of unwanted side effects from illegally acquired cannabis, 14.8%Â said they had problems dosing correctly, and 26.3% had purchased contaminated cannabis.Â
The survey also found 91.7% of respondents said they would prefer cannabis treatment via an app complete with delivery of medical cannabis from a German pharmacy at low prices. Kouparanis said that âPatients no longer need to rely on the illicit market and also should not be pushed in that direction.â  Â
Additionally, the survey found that third of the consumers surveyed have already been diagnosed with a qualifying medical condition by a doctor, while 21.2% had already spoken to a doctor about medical cannabis, but the doctor did not prescribe medical cannabis to them as a treatment. More than a quarter (25.2%) said that doctors were unable to help with their health problems, while just 9.2 percent of those surveyed had âno issuesâ finding a doctor who could competently support them in their therapy with medical cannabis. Â
Dr. Julian Wichmann, M.D., Co-Founder of Bloomwell Group and CEO of Bloomwell, noted that the âfindings underscore the need for medical cannabis to be treated on an equal footing as other modern medical therapies.â Â
âHowever, for too many doctors in Germany, medical cannabis is still a taboo subject,â added Wichmann. âEducation in cannabis medical treatment is needed, not just for patients, but also for medical professionals in order to normalize use and dispel outdated stigmas.âÂ
Get daily cannabis business news updates. Subscribe
Have an additional perspective to share? Send us a message to let us know, and if your comment is chosen by our editors it could be featured here.
Perspective to add? Suggest a revision or submit commentary for review using the form below.
Note: our editors approve comments that provide new and succinct insight to our audience. If your comment is chosen for publishing, it will appear at the end of the article along with your name, job title, and organization. If you have a profile in the Ganjapreneur Business Index, your comment will also include a backlink for reference. If you are suggesting a correction, we will look into the issue further.
TG joined Ganjapreneur in 2014 as a news writer and began hosting the Ganjapreneur podcast in 2016. He is based in upstate New York, where he also teaches media studies at a local university.
Ganjapreneur is made possible by our partners:
“}]] According to a survey from Germany-based medical cannabis company Bloomwell GmBh, 94% of respondents that consumed cannabis did so for at least one medical or health reason. The most common reason cited by respondents for consuming cannabis was for stress relief (about 60%), followed by sleeping dis  Read More Â